Difference between revisions of "Sarcomatoid renal cell carcinoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "====Supportive medications" to "====Supportive therapy") |
m |
||
| Line 11: | Line 11: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
=Metastatic disease, first-line= | =Metastatic disease, first-line= | ||
==Doxorubicin & Gemcitabine {{#subobject:bad0b3|Regimen=1}}== | ==Doxorubicin & Gemcitabine {{#subobject:bad0b3|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:bdc472|Variant=1}}=== | ===Regimen {{#subobject:bdc472|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 60%; text-align:center;" | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
| Line 26: | Line 25: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV push once on day 1 | *[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV push once on day 1 | ||
| Line 33: | Line 33: | ||
**[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 2 or 3, given until day 10 | **[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 2 or 3, given until day 10 | ||
**[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2 | **[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2 | ||
| − | |||
'''14-day cycle for 6 to 9 cycles (cumulative doxorubicin dose of 300 to 450 mg/m<sup>2</sup>, depending on cardiac function)''' | '''14-day cycle for 6 to 9 cycles (cumulative doxorubicin dose of 300 to 450 mg/m<sup>2</sup>, depending on cardiac function)''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# '''ECOG 8802:''' Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012 Jun;29(2):761-7. Epub 2011 Feb 6. [https://doi.org/10.1007/s12032-011-9829-8 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566570/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21298497 PubMed] NCT00068393 | # '''ECOG 8802:''' Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012 Jun;29(2):761-7. Epub 2011 Feb 6. [https://doi.org/10.1007/s12032-011-9829-8 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566570/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21298497 PubMed] NCT00068393 | ||
| − | |||
==Gemcitabine & Sunitinib {{#subobject:ec76af|Regimen=1}}== | ==Gemcitabine & Sunitinib {{#subobject:ec76af|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:py1|Variant=1}}=== | ===Regimen {{#subobject:py1|Variant=1}}=== | ||
{| class="wikitable" style="width: 60%; text-align:center;" | {| class="wikitable" style="width: 60%; text-align:center;" | ||
| Line 52: | Line 50: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8 | *[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Sunitinib (Sutent)]] 37.5 mg PO once per day on days 1 to 14 | *[[Sunitinib (Sutent)]] 37.5 mg PO once per day on days 1 to 14 | ||
| − | |||
'''21-day cycles''' | '''21-day cycles''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# '''MGH 07-212:''' Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 1;121(19):3435-43. Epub 2015 Jun 8. [https://doi.org/10.1002/cncr.29503 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26058385 PubMed] NCT00556049 | # '''MGH 07-212:''' Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 1;121(19):3435-43. Epub 2015 Jun 8. [https://doi.org/10.1002/cncr.29503 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26058385 PubMed] NCT00556049 | ||
| − | |||
[[Category:Sarcomatoid renal cell carcinoma regimens]] | [[Category:Sarcomatoid renal cell carcinoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Renal cell carcinomas]] | [[Category:Renal cell carcinomas]] | ||
Revision as of 23:43, 28 February 2023
Section editor transclusions Note: these are regimens tested in histology-specific populations, please see the main RCC page for other regimens.
2 regimens on this page
2 variants on this page
|
Metastatic disease, first-line
Doxorubicin & Gemcitabine
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Haas et al. 2012 (ECOG 8802) | 2004-2007 | Phase 2 |
Chemotherapy
- Doxorubicin (Adriamycin) 50 mg/m2 IV push once on day 1
- Gemcitabine (Gemzar) 1500 mg/m2 IV over 30 minutes once on day 1
Supportive therapy
- One of the following:
- Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting on day 2 or 3, given until day 10
- Pegfilgrastim (Neulasta) 6 mg SC once on day 2
14-day cycle for 6 to 9 cycles (cumulative doxorubicin dose of 300 to 450 mg/m2, depending on cardiac function)
References
- ECOG 8802: Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012 Jun;29(2):761-7. Epub 2011 Feb 6. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00068393
Gemcitabine & Sunitinib
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Michaelson et al. 2015 (MGH 07-212) | 2007-2013 | Phase 2 |
Chemotherapy
- Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
Targeted therapy
- Sunitinib (Sutent) 37.5 mg PO once per day on days 1 to 14
21-day cycles
References
- MGH 07-212: Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015 Oct 1;121(19):3435-43. Epub 2015 Jun 8. link to original article PubMed NCT00556049